Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Under the agreement, Skyhawk will use its RNA splicing platform, dubbed ...

Reunion Neuroscience’s psychedelic has reduced the symptoms of postpartum depression in a phase 2 study, setting up the ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Jayanta Bhattacharya, M.D., Ph.D., director of the National Institutes of Health (NIH), has called on the agency’s scientific ...

Philips is planning to invest at least $150 million in new funding for its U.S. production base, including through the ...

Experienced business developer Derek Hicks has been handed the reins of Rezo Therapeutics, his first time at the helm of a ...

Omeros’ efforts to get its transplant drug to market have already suffered one FDA rejection. | Omeros’ efforts to get its ...

Evotec’s sweeping reorganization has claimed roughly 600 jobs since last March, 200 more than were originally planned under a ...